Source comparison
BPC-157 Studied GERD: Full Comparison
When evaluating BPC-157 studied GERD against conventional treatments, the comparison isn't apples-to-apples because the evidence bases are fundamentally different. FDA-approved drugs with human clinical trial data versus a research peptide with preclinical ani
This comparison does not assign a generated winner or score.
- When evaluating BPC-157 studied GERD against conventional treatments, the comparison isn't apples-to-apples because the evidence bases are fundamentally different. FDA-approved drugs with human clinical trial data versus a research peptide with preclinical animal model findings. This table maps the key differentiators.
- Proton Pump Inhibitors (omeprazole, esomeprazole)
- Irreversibly block H+/K+-ATPase enzyme in gastric parietal cells, reducing acid secretion by 90–95%
- Multiple Phase III RCTs in humans; FDA-approved for erosive esophagitis
- 4–8 weeks for mucosal healing in 80–90% of patients (endoscopic confirmation)
- FDA-approved, prescription and OTC formulations available
- Gold standard for acid suppression; does not address tissue regeneration; long-term use (>1 year) associated with nutrient malabsorption, fracture risk, C. diff infection
- H2 Receptor Antagonists (ranitidine, famotidine)
- Competitively block histamine H2 receptors on parietal cells, reducing acid output by 60–70%
- Phase III human trials; FDA-approved
- 8–12 weeks for symptom control; less effective for erosive esophagitis than PPIs
- FDA-approved, OTC and prescription
- Less potent than PPIs; tachyphylaxis (tolerance) develops within 2 weeks of continuous use; suitable for mild GERD only
- BPC-157 (synthetic pentadecapeptide)
- Upregulates VEGF and modulates nitric oxide pathways; stimulates angiogenesis, fibroblast recruitment, and collagen deposition in damaged mucosa
- Animal studies only (rodent esophagitis models); no human clinical trials
- 7–14 days for 60–80% ulcer area reduction in rodent models (macroscopic and histological measurement)
- Not FDA-approved; available as research compound via compounding pharmacies
- Mechanistically plausible for tissue regeneration; human dosing, safety, and efficacy entirely extrapolated from animal data; no quality control standards for commercial peptide products
- Alginate/Antacid Combinations (Gaviscon)
- Forms physical raft barrier on stomach contents, preventing reflux; neutralises existing acid
- Limited human studies; OTC approved as symptom relief, not healing agent
- Immediate symptom relief; no evidence of mucosal healing
- FDA-approved as antacid; GRAS (generally recognised as safe)
- Purely symptomatic; does not alter disease progression or heal existing damage; useful for breakthrough symptoms on PPI therapy